Adavosertib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Serous Carcinoma
Conditions
Uterine Serous Carcinoma
Trial Timeline
Nov 30, 2020 → Feb 7, 2023
NCT ID
NCT04590248About Adavosertib
Adavosertib is a phase 2 stage product being developed by AstraZeneca for Uterine Serous Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04590248. Target conditions include Uterine Serous Carcinoma.
What happened to similar drugs?
4 of 18 similar drugs in Uterine Serous Carcinoma were approved
Approved (4) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04949425 | Phase 1 | Terminated |
| NCT04590248 | Phase 2 | Completed |
Competing Products
20 competing products in Uterine Serous Carcinoma